<HashMap><database>biostudies-other</database><scores/><additional><omics_type>Unknown</omics_type><volume>333 ( Pt 3)</volume><submitter>Ankrom MA</submitter><funding>NIAMS NIH HHS</funding><journal>The Biochemical journal</journal><pagination>787-94</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC1219645</full_dataset_link><abstract>Oestrogen receptors (ERs) are present in human osteoblasts and mediate anti-resorptive effects on bone. Human osteoblast-like cells derived from different aged healthy female donors not on hormone replacement therapy were utilized under well-defined conditions in vitro to investigate ER function and levels. Treatment with 0.1 nM oestradiol-17beta of cell strains derived from eight young women (less than 50 years of age) increased hydroxyproline levels significantly [an average (2.2+/-0.1 S.E.M.)-fold increase], whereas cells derived from nine older women (more than 50 years of age) were not significantly affected. Similarly, cell strains, derived from younger women, transfected with a consensus oestrogen-responsive element linked to chloramphenicol acetyltransferase exhibited a greater response to oestrogen than strains derived from older women. When basal ERalpha levels were measured by enzyme immunoassay and normalized on a per cell basis, osteoblast-like strains derived from younger women (n=24) had a mean value of 2.54+/-0.16 fmol of ERalpha per 10(6) cells. In contrast, strains derived from older women (n=20) had a mean value of 5.44+/-0.48 fmol of ERalpha per 10(6) cells. An age-related increase in ERalpha number was also observed in human skin-derived fibroblasts and directly in dermal biopsies from women not on hormone replacement therapy. The results demonstrate ligand concentration-dependent ERalpha induction and indicate a loss of receptor regulation and diminution of ligand-receptor signal transduction with increasing donor age.</abstract><repository>biostudies-other</repository><funding_grant_id>AR 42358</funding_grant_id><data_source>Europe PMC</data_source><pubmed_authors>Ankrom MA</pubmed_authors><pubmed_authors>d'Avis PY</pubmed_authors><pubmed_authors>Blackman MR</pubmed_authors><pubmed_authors>Vetter UK</pubmed_authors><pubmed_authors>Tayback M</pubmed_authors><pubmed_authors>Shapiro JR</pubmed_authors><pubmed_authors>Sponseller PD</pubmed_authors><pubmed_authors>Robey PG</pubmed_authors><pubmed_authors>Patterson JA</pubmed_authors><pubmed_authors>Fedarko NS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Age-related changes in human oestrogen receptor alpha function and levels in osteoblasts.</name><description>Oestrogen receptors (ERs) are present in human osteoblasts and mediate anti-resorptive effects on bone. Human osteoblast-like cells derived from different aged healthy female donors not on hormone replacement therapy were utilized under well-defined conditions in vitro to investigate ER function and levels. Treatment with 0.1 nM oestradiol-17beta of cell strains derived from eight young women (less than 50 years of age) increased hydroxyproline levels significantly [an average (2.2+/-0.1 S.E.M.)-fold increase], whereas cells derived from nine older women (more than 50 years of age) were not significantly affected. Similarly, cell strains, derived from younger women, transfected with a consensus oestrogen-responsive element linked to chloramphenicol acetyltransferase exhibited a greater response to oestrogen than strains derived from older women. When basal ERalpha levels were measured by enzyme immunoassay and normalized on a per cell basis, osteoblast-like strains derived from younger women (n=24) had a mean value of 2.54+/-0.16 fmol of ERalpha per 10(6) cells. In contrast, strains derived from older women (n=20) had a mean value of 5.44+/-0.48 fmol of ERalpha per 10(6) cells. An age-related increase in ERalpha number was also observed in human skin-derived fibroblasts and directly in dermal biopsies from women not on hormone replacement therapy. The results demonstrate ligand concentration-dependent ERalpha induction and indicate a loss of receptor regulation and diminution of ligand-receptor signal transduction with increasing donor age.</description><dates><release>1998-01-01T00:00:00Z</release><publication>1998 Aug</publication><modification>2019-08-04T07:08:03Z</modification><creation>2019-08-04T07:08:03Z</creation></dates><accession>S-EPMC1219645</accession><cross_references/></HashMap>